A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an iga response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil ...

Longer chain antigenic o-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzb. Bacteria expressing a chosen wzz gene have modified o-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer o-polysaccharides. The lps ...

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e. G., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e. G. Tumor cells). Antigens may be, for example, dna that results ...

The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to ccr4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination ...

The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon her2-mediated signaling.

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further ...

Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to t-cells. The peptides utilized in the compositions display high levels of binding with hla-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions ...

The present invention encompasses a cancer vaccine therapy targeting aspartyl-[asparaginyl]-,8-hydroxylase (haah). The present invention contemplate bacteriophage expressing haah peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine ...

Compositions relating to thermostable vaccines and methods of preparing same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.

The present invention relates to peptides comprising at least one cd4+ t epitope, which is immunodominant in vitro, of the cyclin b1 tumor antigen, said peptides being capable of stimulating a specific human cd4+ t lymphocyte response in subjects who have varied hla ii molecules, and to the use of these peptides as a cancer vaccine and as a reagent ...

Disclosed herein is a vaccine comprising an antigen and cd40l. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with s. Pyogenes dna that expresses an emm protein on the cell surface and cytosol. Treatment of cancer patients with an emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity ...

The present invention provides cancer stem cell vaccines useful for treating or preventing a variety of tumors, as well as related methods of producing cancer stem cells and antigens thereof and producing vaccine adjuvants with enhanced activity for use with the stem cell vaccines.

Compositions of either the rm86texas protein from a texas outbreak strain of the southern cattle fever tick, rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this rm86texas protein, are effective for eliciting a protective immune response in non-bovine animals. The rm86texas protein is immunogenic and can be administered as a protein vaccine, ...

A platform enabling the manufacture of thermostable vaccines by incorporating recombinantly expressed, viral envelope proteins in their native conformation into ether glycerophospholipid nanodisc structures that simulate the natural environment of the envelope proteins. The ether glycerophospholipids include ether-linked hydrophobic side chains, and are derived from or modeled after those found in thermophile bacteria, which increase thermostability, thereby significantly enhancing the ...

The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly. The capacitance spacer block is thermally ...

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

The present invention relates to the field of cadv vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing dna and methods of using ...

The present invention relates to equine herpes virus (ehv) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably orf70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgg600 (seq ...

The present invention relates to the field of (vector) vaccines, and especially to the novel ehv insertion site orf70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.